Australia withdraws J&J pelvic mesh

Johnson & Johnson withdraws pelvic mesh device from Australian market

Regulator says the mid-urethral vaginal sling, subject of a class action, is no longer being imported

Melissa Davey @MelissaLDavey

Mon 22 Jan 2018 23.14 EST

• Pharmaceutical giant Johnson & Johnson has withdrawn from the Australian market its supply of the vaginal mesh device that is the subject of a class action before the federal court.

On Tuesday a spokeswoman for Australia’s medical devices regulator, the Therapeutic Goods Administration, confirmed to Guardian Australia that the mid-urethral vaginal sling devices, used to treat stress urinary incontinence in women, were no longer being imported.

The devices are produced by the Johnson & Johnson company Ethicon and no longer appear on the Australian Therapeutic Goods Register, which is a list of products that can be lawfully supplied in Australia. The TGA has not responded to questions about whether the removal of the products from the register also means that products already on hospital shelves cannot be used by surgeons.

The TGA asked all manufacturers of transvaginal sling and mesh devices to update the “instructions for use” on transvaginal mesh and tape products before 17 January to include information about possible adverse events such as severe chronic pain, groin pain and bladder perforation.

According to the TGA, Johnson & Johnson did not meet this deadline and withdrew the supply of their mid-urethral sling devices to enable them to consider their options. A list of pharmaceutical companies that have met the new requirements has been made public.

The president of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, Professor Steve Robson, told Guardian Australia he had written to all members to alert them to the development. It was his understanding that Johnson & Johnson slings already on hospital shelves could still be used but new supplies could not be imported.

Robson said he did not have “exact figures”, but the Johnson & Johnson devices were probably the most widely used by surgeons to treat incontinence.

“What I have heard is once the stock on the shelf is gone that’s it, and many hospitals, if not most, are looking at other options including other brands of urethral tape, which are still available,” Robson said.

“The feedback is some places are exploring transition arrangements so women can be offered other similar products. What I also wrote to our members yesterday was that it is clear mid-urethral tapes are the most appropriate response to incontinence which has not responded to other clinical treatment. We recirculated a Cochrane review that shows that mid-urethral tapes are the most appropriate treatment when used appropriately, and are very safe.

Visit us at WE MOCKINGBIRD STATION D

“In fact, I think it’s regrettable it won’t be available for a while, but there are other similar products.”

The Johnson & Johnson/Ethicon implant became the subject of a class action run by Shine Lawyers in 2017, with 700 Australian women alleging that faulty pelvic mesh implants caused them debilitating pain.

Similar class actions involving thousands of women are also under way in the UK and US. More than 100,000 transvaginal mesh lawsuits have been filed in the US, the largest number against Johnson & Johnson, the manufacturer of the most commonly used meshes. Shine Lawyers alleges Johnson & Johnson failed to properly test the devices and played down their risk to both surgeons and patients.

A Senate inquiry has examined whether any financial or other incentives have been provided to medical practitioners to use or promote transvaginal mesh implants; the lack of data available on how many procedures were performed; and the type and incidence of health problems woman have experienced.

The class action is due to return to the federal court in Sydney on Monday.

Johnson & Johnson has been contacted for comment.

https://www.theguardian.com/society/2018/jan/23/johnson-johnson-withdraws-pelvic-vaginal-mesh-device-from-australian-market

A Ban on Hernia Mesh? NICE !

Welsh patients call for ban on vaginal mesh to treat hernias

10 January 2018  FiDA highlight

Experts are currently looking at the use of vaginal mesh implants in Wales, but the impact on hernia patients is not being considered in the study.

Last month the National Institute for Health and Care Excellence (NICE) recommended mesh operations should be banned from treating organ prolapse.

The Welsh Government said it was outside the scope of its review.

Richard, 67, from Penarth, said the exclusion of hernia patients has been "pretty upsetting".

He has had to give up work as an actor because of the pain, and can no longer stand for too long after several mesh implants for hernias.

"It feels at times like a knife sticking into the wound," he said. "I had hoped to be doing an awful lot more with my time.

What is a hernia?

A hernia occurs when an internal part of the body pushes through a weakness in the muscle or surrounding tissue wall.

In many cases, it causes no or very few symptoms, although people may notice a swelling or lump in their abdomen or groin.

The Royal College of Surgeons said mesh can be the "most effective" way to treat a hernia.

"There's always a small risk with any type of surgery but hernia mesh implants have a lower risk of infection than those used to treat prolapse," it added.

But one former surgeon based in Kent said there needed to be more awareness about any potential complications.

Peter Jones said patients were becoming more aware but "in the main, no they are not warned about the risks".

Plastic mesh implants were also used to ease incontinence and to support organs which have prolapsed after childbirth, but some have caused painful and debilitating complications for patients.

Last month, NICE recommended vaginal mesh operations should be banned for treating organ prolapse in England.

The Welsh Government said the review group has focused on the "use of vaginal mesh and tape for pelvic stress urinary incontinence and vaginal pelvic organ prolapse".

It added all NHS Wales organisations were expected to follow the NICE guidelines. It said the group's work will be completed by the end of the month.

http://www.bbc.com/news/uk-wales-42641633#

Evidence for Device Safety is Inadequate: Transvaginal Mesh

Trials of transvaginal mesh devices for pelvic organ prolapse: a systematic database review of the US FDA approval process

• Carl J Heneghan1, Ben Goldacre1, Igho Onakpoya1, Jeffrey K Aronson1, Tom Jefferson1,2, Annette Pluddemann1, Kamal R Mahtani1

FiDA highlight

Abstract

Introduction Transvaginal mesh devices are approved in the USA by the Food and Drug Administration (FDA), through the 510(k) system. However, there is uncertainty about the benefit to harm balance of mesh approved for pelvic organ prolapse. We, therefore, assessed the evidence at the time of approval for transvaginal mesh products and the impact of safety studies the FDA mandated in 2012 because of emerging harms.

Methods We used FDA databases to determine the evidence for approval of transvaginal mesh. To create a ‘family tree’ of device equivalence, we used the 510(k) regulatory approval of the 1985 Mersilene Mesh (Ethicon) and the 1996 ProteGen Sling (Boston Scientific), searched for all subsequently related device approvals, and for the first published randomised trial evidence. We assessed compliance with all FDA 522 orders issued in 2012 requiring postmarketing surveillance studies.

Results We found 61 devices whose approval ultimately relied on claimed equivalence to the Mersilene Mesh and the ProteGen Sling. We found no clinical trials evidence for these 61 devices at the time of approval. Publication of randomised clinical trials occurred at a median of 5 years after device approval (range 1–14 years). Analysis of 119 FDA 522 orders revealed that in 79 (66%) the manufacturer ceased market distribution of the device, and in 26 (22%) the manufacturer had changed the indication. Only seven studies (six cohorts and new randomised controlled trial) covering 11 orders were recruiting participants (none had reported outcomes).

Conclusions Transvaginal mesh products for pelvic organ prolapse have been approved on the basis of weak evidence over the last 20 years. Devices have inherited approval status from a few products. A publicly accessible registry of licensed invasive devices, with details of marketing status and linked evidence, should be created and maintained at the time of approval.

Strengths and limitations of this study

• We searched a variety of Food and Drug Administration (FDA) summary database providing listings of all FDA 510(k) device clearances since 1976.
• We identified all FDA-522 postmarketing surveillance orders for mesh products issued in 2012.
• Searching the latest Cochrane review on Mesh allowed data to be extracted from all of the published randomised controlled trials comparing transvaginal grafts versus traditional native tissue repair in women with vaginal prolapse.
• Although we searched extensively for mesh-approved devices, we will have failed to identify some products, especially those that may have been withdrawn from the market.
• The lack of a publicly accessible registry of licensed invasive devices with details of marketing status and linked evidence prevents accurate assessment of current status for many implantable devices.
• We were unable to scrutinise the European approval system due to its lack of accessibility. The lack of European approval evidence prevents meaningful comparison between the European and US regulatory systems.

Introduction

Implantable devices, such as non-absorbable polypropylene mesh (‘mesh’), are used for surgical treatment of pelvic prolapse and stress urinary incontinence. While evidence suggests that mid-urethral slings are safe and effective,^{1 2} there have been concerns about the safety of transvaginal mesh used for managing pelvic organ prolapse.^{3 4} A Cochrane review concluded that although permanent transvaginal mesh may reduce the rates of recurrent prolapse, its use is associated with higher rates of reoperation and bladder damage.⁵ In 2011, the Food and Drug Administration (FDA) raised concerns about the safety of some transvaginal mesh products.⁶ Serious adverse events attributed to the use of such products were not rare and included serious complications, such as vaginal erosions, infections and organ perforation.

Implantable devices are approved by the FDA, depending on the class of device. Class II devices are generally approved under the 510(k) process while Class III devices are subject to a Premarket Approval Application (PMA) process. Transvaginal mesh devices were originally included in Class II and required the 510(k) process, but they were reclassified in January 2016. In the 510(k) process, anyone who intends to market a new medical device has to submit a premarketing notification to the FDA at least 90 days before the date scheduled for marketing to begin.⁷ The regulatory system for medical devices has a low threshold for approval and the limited requirement for clinical data, for which it has been criticised.^{8 9} The PMA process¹⁰ imposes a higher standard of evidence for new devices, including clinical trials. However, Section 510(k) of the Food, Drug and Cosmetic Act allows manufacturers to bypass this requirement by seeking approval for new devices because they are ‘substantially equivalent’ to other devices (referred to as predicates) that are already available.¹¹

Section 522 of the Food, Drug and Cosmetic Act gives the FDA the authority to mandate manufacturers to undertake postmarket surveillance studies of Class II or III devices, among other criteria, when ‘failure would be reasonably likely to have serious adverse health consequences … or the device is to be implanted in the body for more than one year’.¹² However, when the FDA asked manufacturers of surgical mesh products to conduct new safety studies in January 2012,¹³ some manufacturers removed their products from the market, thus preventing the proper assessment of the benefit to harm balance of their devices.¹⁴

We set out to systematically assess the nature and quality of the evidence that was available for transvaginal mesh products at the time of their approval by the FDA, and the rate of compliance with orders requiring manufacturers to generate better evidence in response to concerns about harms after approval. We also set out to characterise how assumptions of device equivalence have been used during approvals by mapping the network of devices approved on the basis of equivalence to earlier devices, back to one pivotal device withdrawn from the market two decades ago.

Methods

Approvals and device equivalence

To assess the extent to which device equivalence underpins approval of modern mesh products, we used the 510(k) regulatory approval (K851086) of the 1985 Mersilene Mesh (Ethicon) and the (K963226) 1996 ProteGen Sling (Boston Scientific) to search for related device approvals. We used the FDA summary database for 510(k) Premarket Notification,¹⁵ the 510 k.directory/search directory¹⁶ and fdazilla.com to search for approvals.¹⁷ In combination, these searchable databases provided complete listings of all FDA 510(k) device clearances since 1976, with image PDFs converted into searchable documents using Optical Character Recognition. They also facilitated forward and backward navigation of cross-referenced device applications. Once we found a device in the tree, we then searched for further approvals of that device using the 510(k) number. We developed a ‘family tree of equivalence’ for devices that included the 510(k) number, the year of approval and the current status of the device. We also searched the 510(k) applications using 510kdecisions.com,¹⁸ which contains >132000 FDA 510(k) applications submitted since May 1976 for relevant clinical trial evidence for that application.

Randomised trials evidence in the year of approval

We extracted the year of publication from the first published randomised trials for a vaginal mesh product that was included in the Cochrane review published on February 2016.⁵ This review evaluated 37 randomised controlled trials (RCTs) comparing transvaginal grafts versus traditional native tissue repair in women with vaginal prolapse. We then located the relevant trial device 510(k) application and extracted its year of approval to establish the time from approval to trial publication.

Postmarketing surveillance studies: 522 orders analysis

We identified all FDA-522 postmarketing surveillance orders for mesh products issued in 2012.¹² These were obtained from the FDA’s searchable resource¹⁹ containing current information on the status of all 522 postmarket surveillance studies. All 522 orders issued in 2012 were obtained, and from these, we extracted all mesh devices named the 510(k) orders, and the current status of the orders, whether active or inactive. We further extracted the reasons underlying the inactive orders and the amount of evidence about the active orders and their reporting status (on the fifth of every month the FDA website posts revised data on interim or final reports).¹²

Patient involvement

The ideas and design of this study have been formed through long-standing discussions with members of the public, those involved in litigation and members of the media.

Results

Approvals and device equivalence

We found 61 devices related to the 1996 approval of the ProteGen Sling (Boston Scientific; K963226, 1996) and Ethicon’s Mersilene Mesh, which has been used for treating hernias since 1954 (Ethicon K851086, 1985). Figure 1 shows the chain of approvals for these two devices. Searching for the ProteGen ID number K963226k retrieved 22 associated clearances. As examples, these included the 1997 Influence IN-SLING (K972651)²⁰ and the 1998 Tension Free Transvaginal tape (K974098),²¹ which generated the forward chain.

Figure 1

Food and Drug Administration device chain approval for transvaginal mesh.

Figure 1 also shows that the chain of device approvals using ‘substantial equivalence’ can be traced back through more than one predicate, providing a confusing picture. Newer devices are compared with various older devices, and devices with similar names are compared with each other. For example, the 2008: Avaulta Solo Support System K082571²² has been compared with the 2009: Avaulta Solo Support System K083839, part of the same system.²³ Some devices have been removed from the market (eg, 2008: IVS. Tunneller device, Covidien UK; K073164),²⁴ and some have had changes to their indications over time (eg, 2002: Surgical Mesh, Boston Scientific; K020110).^{25 26}

Randomised trials evidence in the year of approval

We found no clinical trial evidence for any of the devices shown in figure 1 in the 510(k) submissions at the time of approval. Table 1 shows that we were able to trace the year of approval and the relevant approval documentation for 29 of 33 different mesh products. In no case was the trial published before approval, and publication occurred at a median of 5 years after approval, range 1 (Gynecare Prolift Ethicon)²⁷ to 14 years (Sofradim, Parieten).²⁸

Table 1

Comparison of randomised controlled trial publication date of transvaginal mesh and date of US FDA approval

Postmarketing surveillance studies: 522 orders analysis

From the FDA’s website,¹⁹ we retrieved 119 orders in 2012 relating to the manufacturers of 126 different vaginal mesh devices, marketed by 34 different companies, 23 of which marketed at least two devices (Search date March 2017). Four companies covered 43% of the orders (American Medical Systems, Boston Scientific, Coloplast Corporation and Synovis Surgical Innovations/Baxter) (see online supplementary web table).

Supplementary file 1

Analysis of the 119 orders showed that in 79 (66%) the manufacturer ceased market distribution of the device subject to the postmarketing surveillance order (if the manufacturer resumes device distribution, they will be required to address the postmarketing surveillance order); in 26 (22%) the 522 orders no longer applied (the indication for use had been revised and no longer included the indication subject of the 522 orders); for 2 (1.7%) orders the manufacturer (Shellhigh) reported that it was no longer in business; and 1 order reported that the device was not a vaginal mesh product. Only 11 orders (9.4%) reported that they were undertaking postmarketing studies. In four orders. the manufacturer requested that their multiple orders should be consolidated into one, leaving a total of seven studies (six cohorts and one RCT) including 2756 participants recruiting (none had reported outcomes).

Discussion

Summary

Our analysis shows a consistent pattern of device approval through the use of ‘substantial equivalence’, with chains of equivalence that ultimately lead back to the Mersilene Mesh. Clinical trials evidence did not form part of the approval process, and when trials were conducted, they occurred a considerable time later (up to 14 years). After the FDA 522 orders requiring postmarketing studies were issued, many manufacturers removed their devices from the market without performing the required research; only seven studies were performed at that stage, and none reported outcomes. Thus, in most cases, there was no opportunity to determine whether the marketed devices had a favourable benefit to harm balance.

Limitations

Though we searched extensively for meshes approved through the FDA 510(k) process, we have failed to identify some of the products, especially those that may have been withdrawn from the market. The withdrawal of some mesh products from the market prevents us from precisely assessing the quality of the evidence for the clinical effectiveness of such products. The failure to identify any clinical trials before regulatory approval of transvaginal meshes casts some doubts on the criteria used by the FDA to grant marketing authorisations for the products; this is further compounded by the lack of postmarketing surveillance for most of the approved products. It is therefore highly likely that more devices could be found in the chain of equivalence shown in figure 1.

Over 100 devices manufactured by at least 40 different companies have at some point been in circulation. A real-time database is needed to allow patients, clinicians and regulators the opportunity to view, and understand, the regulatory chain of any device alongside the evidence used at the time of its approval. We have focused on the USA, which is the only regulatory system that provides transparent access to approvals (called ‘clearances’). In the European Union, approval is overseen by Notified Bodies and is a closed access system²⁹; therefore, it is impossible to scrutinise the European approval system, given its lack of accessibility. The lack of evidence to assess devices approved in Europe prevents meaningful comparison between the European Medicines Agency and FDA regulatory systems.

Findings in context

A US study of devices cleared through the 510(k) process in 2008 found 1105 predicates for 43 new implantable devices. Only eight devices demonstrated evidence to support substantial equivalence of previously cleared devices: most studies provided no data, highlighting the lack of publicly available evidence.^{9 30} A 2011 analysis of 113 devices recalled because of life-threatening harms showed that recalled Class III devices were often approved using the less burdensome 510(k) process.³¹ In February 2012, partly in response to problems with transvaginal mesh devices and to address the risk of harms, the US Congress introduced a bill that aimed to alter the 510(k) approval process, and in January 2016 the FDA changed the approval requirements for surgical mesh from Class II to the higher risk Class III. Some mesh devices have been documented as having been marketed in the USA without approval: for example, Johnson & Johnson brought the Gynecare Prolift (K071512) to market in 2005, 3 years before it received regulatory approval, as reported by Bloomberg.³² A previous family tree of the type we present included 16 products.³³

Implications

In the USA, the Medical Device Amendment of 1976 decreed that the FDA would review all existing medical devices and put them into one of three classes (Class I, lowest risk; Class II, moderate risk; and Class III, highest risk).³⁴ Once existing devices were classified, all new devices for use in humans were to be labelled as Class III, requiring PMA, which can require evidence from well-controlled investigations (but can also be granted on the basis of lower-quality evidence).³⁵ As the classification of existing devices took >14 years to complete, legislation allowed mesh devices that were developed after 1976 to be approved without the need for clinical data. Consequently, the higher standards required by the PreMarket Approval process for Class III devices were in fact not applied, and mesh devices have consistently used the ‘substantially equivalent’ claim to ensure market access through the less burdensome 510(k) route.

While the PMA route requires clinical data, 510(k) focuses primarily on mechanical performance and material safety; requiring bench and/or animal testing to confirm that certain technical specifications are met, and evidence that mesh is biocompatible. However, the 510(k) regulation allows approval to be obtained by comparison with a chain of equivalent devices, rather than through well-designed clinical trials, which would be preferable.

In response to FDA 522 orders, manufacturers have withdrawn from the market a substantial number of lifelong implantable devices that had not been subjected to clinical trials, leaving uncertainties about their relative benefits and harms. Devices are not subjected to the well-tested methods that have for many years been applied to medicinal products, and this has important implications. For example, a device, the Exhale Drug-Eluting Stent, which appeared to be effective in a phase II study, was found to be ineffective and harmful in phase III.^{36 37} Furthermore, the FDA has recently reported 22 case studies of drugs, vaccines and medical devices for which promising phase II clinical trial results were not confirmed in phase III studies.³⁸ Better designed and adequately powered trials are required to allow for better assessment of the benefit to harm balance of transvaginal meshes in those most likely to gain some benefit for the repair of pelvic organ prolapse.

Transvaginal mesh for pelvic organ prolapse has not even generally been subjected to adequate clinical studies at any phase of its development. The available trials have been poorly designed and poorly conducted and have failed to account for variable lengths of patient follow-up, underlining the importance of properly designed clinical trials during the development of devices and careful postmarketing surveillance. The IDEAL collaboration has proposed a framework for life-cycle product evaluation whereby devices could be tested before and after marketing.^{38 39} One such study trialling the benefits and harms of transvaginal mesh for pelvic organ prolapse based on the IDEAL framework was recently published.⁴⁰

In 2016, device manufacturers, the FDA and professional organisations established the Pelvic Floor Disorders Registry.⁴¹ Postmarketing studies and registries of patients treated with such devices should be mandatory at the time of approval.

Conclusions

Our findings highlight the lack of evidence used for licensing transvaginal mesh products. When evidence has been forthcoming, it has often emerged too late to inform clinical practice. The current systems for ensuring patient safety are inadequate for medical devices. We think that clinical trials evidence should be mandatory for marketing authorisation of implantable devices and that there should be incentives for the development of high-quality evidence-based devices. A publicly accessible registry of licensed invasive devices with details of marketing status and linked evidence should be created and maintained.

References

• 1 1.↵ Ford AA , Rogerson L , Cody JD , et al . Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev 2015:CD006375.doi:10.1002/14651858.CD006375.pub3 Google Scholar
• 1 2.↵ Nager CW . Midurethral slings: evidence-based medicine vs the medicolegal system. Am J Obstet Gynecol 2016;214:708.e1–5.doi:10.1016/j.ajog.2016.04.018 Google Scholar
• 1 3.↵ Diwadkar GB , Barber MD , Feiner B , et al . Complication and reoperation rates after apical vaginal prolapse surgical repair: a systematic review. Obstet Gynecol 2009;113:367–73.doi:10.1097/AOG.0b013e318195888d CrossRefPubMedGoogle Scholar
• 1 4.↵ Feiner B , Jelovsek JE , Maher C . Efficacy and safety of transvaginal mesh kits in the treatment of prolapse of the vaginal apex: a systematic review. BJOG 2009;116:15–24.doi:10.1111/j.1471-0528.2008.02023.x PubMedGoogle Scholar
• 1 5.↵ Maher C , Feiner B , Baessler K , et al . Transvaginal mesh or grafts compared with native tissue repair for vaginal prolapse. Cochrane Database of Systematic Reviews, 2016.Google Scholar
• 6.↵Urogynecologic surgical mesh. http://www.fda.gov/downloads/medicaldevices/safety/alertsandnotices/UCM262760.pdf (accessed 7 Mar 2017).Google Scholar
• 7.↵US Food and Drug Administration. The new 510(k) paradigm - alternate approaches to demonstrating substantial equivalence in premarket notifications - final guidance. http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080189.pdf (accessed 7 Mar 2017).Google Scholar
• 8.↵Institute of Medicine,Board on Population Health and Public Health Practice, Committee onthe Public Health Effectiveness of the FDA 510(k) Clearance Process. Medical devices and the public’s health: The FDA 510(k) clearance process at 35 Years. National Academies Press, 2011.Google Scholar
• 1 9.↵ Zuckerman D , Brown P , Das A . Lack of publicly available scientific evidence on the safety and effectiveness of implanted medical devices. JAMA Intern Med 2014;174:1781–7.doi:10.1001/jamainternmed.2014.4193 CrossRefPubMedGoogle Scholar
• 10.↵Devices CF, Health R. PMA approvals. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/pmaapprovals/default.htm (accessed 7 Mar 2017).Google Scholar
• 11.↵Devices CF, Health R. 510(k) Clearances. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/510kClearances/ (accessed 7 Mar 2017).Google Scholar
• 12.↵Devices CF, Health R. 522 Postmarket Surveillance Studies - 522 Postmarket Surveillance Studies – Frequently Asked Questions (FAQs). http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/PostmarketSurveillance/ucm134497.htm (accessed 7 Mar 2017).Google Scholar
• 13.↵Press Announcements - FDA issues proposals to address risks associated with surgical mesh for transvaginal repair of pelvic organ prolapse. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm395192.htm (accessed 7 Mar 2017).Google Scholar
• 14.↵Drug Watch. Transvaginal mesh brands – dangerous mesh implants & brands. https://www.drugwatch.com/transvaginal-mesh/brands/ (accessed 7 Mar 2017).Google Scholar
• 15.↵510(k) premarket notification. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm (accessed 7 Mar 2017).Google Scholar
• 16.↵510(k) directory -database of 145937 FDA premarket notification decisions, and counting. https://510k.directory (accessed 7 Mar 2017).Google Scholar
• 17.↵https://fdazilla.com/. https://fdazilla.com/medical-devices (accessed 7 Mar 2017).Google Scholar
• 18.↵http://www.510kdecisions.com/ (accessed 7 Mar 2017).Google Scholar
• 19.↵522 postmarket surveillance studies. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm (accessed 7 Mar 2017).Google Scholar
• 20.↵K972651. http://www.accessdata.fda.gov/cdrh_docs/pdf/K972651.pdf (accessed 7 Mar 2017).Google Scholar
• 21.↵K974098. http://www.accessdata.fda.gov/cdrh_docs/pdf/K974098.pdf (accessed 7 Mar 2017).Google Scholar
• 22.↵K082571. https://www.accessdata.fda.gov/cdrh_docs/pdf8/K082571.pdf (accessed 7 Mar 2017).Google Scholar
• 23.↵K083839. http://www.accessdata.fda.gov/cdrh_docs/pdf8/K083839.pdf (accessed 7 Mar 2017).Google Scholar
• 24.↵K073164. http://www.accessdata.fda.gov/cdrh_docs/pdf7/K073164.pdf (accessed 7 Mar 2017).Google Scholar
• 25.↵http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm?t_id=319&c_id=836 (accessed 7 Mar 2017).Google Scholar
• 26.↵K020110. http://www.accessdata.fda.gov/cdrh_docs/pdf2/K020110.pdf (accessed 7 Mar 2017).Google Scholar
• 27.↵Oral presentations. Int Urogynecol J 2009;20:73–239.Google Scholar
• 1 28.↵ Turgal M , Sivaslioglu A , Yildiz A , et al . Anatomical and functional assessment of anterior colporrhaphy versus polypropylene mesh surgery in cystocele treatment. Eur J Obstet Gynecol Reprod Biol 2013;170:555–8.doi:10.1016/j.ejogrb.2013.07.014 Google Scholar
• 1 29.↵ Thompson M , Heneghan C , Billingsley M , et al . Medical device recalls and transparency in the UK. BMJ 2011;342:d2973.doi:10.1136/bmj.d2973 FREE Full TextGoogle Scholar
• 1 30.↵ Heneghan C , Thompson M , Billingsley M , et al . Medical-device recalls in the UK and the device-regulation process: retrospective review of safety notices and alerts. BMJ Open 2011;1:e000155.doi:10.1136/bmjopen-2011-000155 Google Scholar
• 1 31.↵ Zuckerman DM , Brown P , Nissen SE . Medical device recalls and the FDA approval process. Arch Intern Med 2011;171:1006–11.doi:10.1001/archinternmed.2011.30 CrossRefPubMedWeb of ScienceGoogle Scholar
• 32.↵J&J marketedvaginal mesh implant without U.S. approval. http://www.bloomberg.com/news/articles/2012-03-21/j-j-sold-vaginal-mesh-implant-without-u-s-regulatory-approval (accessed 7 Mar 2017).Google Scholar
• 33.↵http://www.fleming-law.com/documents/vmds-correction-of-pelvic-organ-prolapse-part1.pdf (accessed 21 Jul 2017).Google Scholar
• 34.↵Medical devices amendment act 1976. https://www.gpo.gov/fdsys/pkg/STATUTE-90/pdf/STATUTE-90-Pg539.pdf (accessed 7 Mar 2017).Google Scholar
• 35.↵Devices CF, Health R. Premarket approval(PMA) - PMA clinical studies. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/PremarketSubmissions/PremarketApprovalPMA/ucm050419.htm (accessed 7 Mar 2017).Google Scholar
• 1 36.↵ Cardoso PF , Snell GI , Hopkins P , et al . Clinical application of airway bypass with paclitaxel-eluting stents: early results. J Thorac Cardiovasc Surg 2007;134:974–81.doi:10.1016/j.jtcvs.2007.05.040 CrossRefPubMedWeb of ScienceGoogle Scholar
• 1 37.↵ Shah PL , Slebos DJ , Cardoso PF , et al . Design of the exhale airway stents for emphysema (EASE) trial: an endoscopic procedure for reducing hyperinflation. BMC Pulm Med 2011;11:1.doi:10.1186/1471-2466-11-1 CrossRefPubMedGoogle Scholar
• 38.↵U.S. Department of Health and Human Services https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM535780.pdf (accessed 21 Jul 2017).Google Scholar
• 1 39.↵ Sedrakyan A , Campbell B , Merino JG , et al . IDEAL-D: a rational framework for evaluating and regulating the use of medical devices. BMJ 2016;353:i2372.doi:10.1136/bmj.i2372 FREE Full TextGoogle Scholar
• 1 40.↵ Barski D , Arndt C , Gerullis H , et al . Transvaginal PVDF-mesh for cystocele repair: a cohort study. Int J Surg 2017;39:249–54.doi:10.1016/j.ijsu.2017.02.006 Google Scholar
• 1 41.↵ Bradley CS , Visco AG , Weber LeBrun EE , et al . The pelvic floor disorders registry: Purpose and development. Female Pelvic Med Reconstr Surg 2016;22:77–82.doi:10.1097/SPV.0000000000000254 Google Scholar

View Abstract

Footnotes

• Contributors CJH designed the study, collected the data and drafted the first version for the manuscript. IO, BG, AP, JKA, TJ and KRM contributed to the data interpretation and development of the manuscript and approved the final draft. CJH is the guarantor.
• Disclaimer The views expressed are those of the authors.
• Competing interests CJH is an expert witness in a current medical device legal case and has received financial remuneration from an asbestos legal case. He has received expenses in the past from the US FDA to attend a working group on device regulation. CJH and BG receive funding from the National Institute of Health Research (NIHR) School of Primary Care. BG receives funding from the Laura and John Arnold Foundation and reports personal fees from intermittent additional personal income from speaking and writing for lay audiences on problems in science and medicine including regulatory shortcomings. TJ and CJH were recipients of a UK National Institute for Health Research grant for a Cochrane review of neuraminidase inhibitors for preventing and treating influenza. Also, TJ receives royalties from his books published by Il Pensiero Scientifico Editore, Rome and Blackwells. TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products. In 2011-2013, TJ acted as an expert witness in a litigation case related to the antiviral oseltamivir, in two litigation cases on potential vaccine-related damage, and in a labour case on influenza vaccines in healthcare workers in Canada. He has acted as a consultant for Roche (1997-1999), GSK (2001-2002), Sanofi-Synthelabo (2003) and IMS Health (2013), and in 2014 was retained as a scientific adviser to a legal team acting on oseltamivir. In 2014-2016 TJ was a member of three advisory boards for Boehringer Ingelheim and is the holder of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews. In 2016-2017 TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine. JKA has published papers and edited textbooks on adverse drug reactions; he has also acted as an expert witness in cases related to adverse drug reactions.
• Provenance and peer review Not commissioned; externally peer reviewed.
• Data sharing statement A spreadsheet recording the individual 522 orders is available on request from the corresponding author.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information: © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

http://bmjopen.bmj.com/content/7/12/e017125